Fig. 6

a Antimicrobial activities of the embryo extract against M. luteus and E. coli. b The early (8-cell stage) embryos were first microinjected with PBS, BSA, anti-β-actin antibody (AcAb), anti-ELAVL1a antibody (ELAVL1aAb), rELAVL1a, and rELAVL1a plus AcAb or rELAVL1a plus ELAVL1aAb and then challenged by injection with live A. hydrophila (8.3 × 107 cells/ml). The development of the embryos was observed, and the cumulative mortality rate was calculated at 24 h after bacterial injection. c Western blotting analysis of the efficacy of elavl1a-MO. β-Actin was used as control. Lane 1, 2, 3, the levels of ELAVL1a and β-Actin in the embryos injected with control morpholino (1), elavl1a-MO (2), or co-injection of elavl1a-MO plus elavl1a-mRNA (3). d The reduced antibacterial activity of the elavl1a-MO-knockdown embryos. The 24-h mortality of elavl1a-MO-knockdown group, control group, and rescued group, after the challenge with live A. hydrophila (8.3 × 107 cells/ml). All data were expressed as mean values ± S.D. (n = 3). The data are from three independent experiments performed in triplicate. The bars represent the mean ± SD. The significance of the difference was determined by one-way ANOVA. *p < 0.05. M, marker; con, control; Ex, embryo extract; AcAb, anti-β-actin antibody; ELAVL1aAb, mouse anti-ELAVL1a antibody.